TY - JOUR
T1 - Stage II endometrial carcinoma treated with external-beam radiotherapy, intracavitary application of cesium, and surgery
AU - Podczaski, Edward S.
AU - Kaminski, Paul
AU - Manetta, Alberto
AU - Louk, Douglas
AU - Andrews, Charles
AU - Larson, James
AU - DeGeest, Koen
AU - Mortel, Rodrigue
PY - 1989/11
Y1 - 1989/11
N2 - From September 1972 to September 1987, thirty-six patients with stage II carcinoma of the endometrium were treated with external-beam radiotherapy to the pelvis, a single intracavitary application of cesium-137, and extrafascial hysterectomy with adnexectomy. Patients were followed for a median of 54.4 months. Overall 2- and 5-year actuarial survival rates were 83 and 58%, respectively. Survival was analyzed in terms of the independent variables surgical stage, presence of a gross cervical lesion, and residual disease within the myometrium or cervix. Factors contribuing to patients survival were analyzed by the log-rank method. The 12 patients with a gross cervical lesion had an adverse prognosis, as compared to those without such a lesion (P < 0.05). Seven of the twelve patients (58%) with a cervical lesion at clinical staging demonstrated persistent or recurrent disease. The presence of extrauterine disease at surgery was a major prognostic factor in patient survival (P < 0.01). All six patients with extrauterine disease expired 2.3 to 53.0 months after hysterectomy. Two patients with persistence of disease expired 2.3 and 7.5 months after hysterectomy. Eleven patients developed recurrent disease 2.1 to 56.5 months after hysterectomy. All presented with distant metastases. Four of the thirteen patients with persistent or recurrent disease had no residual tumor within the myometrium.
AB - From September 1972 to September 1987, thirty-six patients with stage II carcinoma of the endometrium were treated with external-beam radiotherapy to the pelvis, a single intracavitary application of cesium-137, and extrafascial hysterectomy with adnexectomy. Patients were followed for a median of 54.4 months. Overall 2- and 5-year actuarial survival rates were 83 and 58%, respectively. Survival was analyzed in terms of the independent variables surgical stage, presence of a gross cervical lesion, and residual disease within the myometrium or cervix. Factors contribuing to patients survival were analyzed by the log-rank method. The 12 patients with a gross cervical lesion had an adverse prognosis, as compared to those without such a lesion (P < 0.05). Seven of the twelve patients (58%) with a cervical lesion at clinical staging demonstrated persistent or recurrent disease. The presence of extrauterine disease at surgery was a major prognostic factor in patient survival (P < 0.01). All six patients with extrauterine disease expired 2.3 to 53.0 months after hysterectomy. Two patients with persistence of disease expired 2.3 and 7.5 months after hysterectomy. Eleven patients developed recurrent disease 2.1 to 56.5 months after hysterectomy. All presented with distant metastases. Four of the thirteen patients with persistent or recurrent disease had no residual tumor within the myometrium.
UR - http://www.scopus.com/inward/record.url?scp=0024434435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024434435&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(89)90054-1
DO - 10.1016/0090-8258(89)90054-1
M3 - Article
C2 - 2807019
AN - SCOPUS:0024434435
SN - 0090-8258
VL - 35
SP - 251
EP - 254
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -